Medicine and Dentistry
Hidradenitis Suppurativa
100%
Cohort Analysis
33%
Biological Product
24%
Disease
17%
Quality of Life
16%
Retinoid
16%
Wound Closure
16%
Infliximab
16%
Adalimumab
16%
Major Surgery
16%
Guselkumab
16%
Disease Burden
16%
Action Study
16%
Clinical Trial
11%
Survival Time
10%
Dermatosis
10%
Etretin
9%
Disease Duration
8%
Patient-Reported Outcome
7%
Isotretinoin
7%
Kaplan Meier Method
6%
Proportional Hazards Model
6%
Survival Rate
6%
Disease Severity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Suppurative Hidradenitis
100%
Cohort Study
34%
Biological Product
23%
Prevalence
21%
Infliximab
16%
Wound
16%
Disease
16%
Comorbidity
16%
Adalimumab
16%
Guselkumab
16%
Retinoid
16%
Survival Rate
13%
Survival Time
10%
Etretin
9%
Disease Duration
8%
Isotretinoin
7%
Keyphrases
Hidradenitis Suppurativa
33%
Disease Burden
16%
Dutch Cohort
16%
Comorbidity
16%
Tool Classification
16%
Population-based
16%
Guselkumab
16%
Smoking Behavior
16%
Socioeconomic Status
16%
Infectiveness
5%
